HRP20241231T1 - Tetrahidropiridopirazin modulatori gpr6 - Google Patents

Tetrahidropiridopirazin modulatori gpr6 Download PDF

Info

Publication number
HRP20241231T1
HRP20241231T1 HRP20241231TT HRP20241231T HRP20241231T1 HR P20241231 T1 HRP20241231 T1 HR P20241231T1 HR P20241231T T HRP20241231T T HR P20241231TT HR P20241231 T HRP20241231 T HR P20241231T HR P20241231 T1 HRP20241231 T1 HR P20241231T1
Authority
HR
Croatia
Prior art keywords
disease
pharmaceutically acceptable
compound
acceptable salt
group
Prior art date
Application number
HRP20241231TT
Other languages
English (en)
Croatian (hr)
Inventor
Jason W. Brown
Stephen Hitchcock
Maria HOPKINS
Shota Kikuchi
Holger Monenschein
Holly REICHARD
Kristin SCHLEICHER
Huikai SUN
Todd MACKLIN
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20241231T1 publication Critical patent/HRP20241231T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20241231TT 2017-06-15 2018-06-15 Tetrahidropiridopirazin modulatori gpr6 HRP20241231T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US201862672261P 2018-05-16 2018-05-16
PCT/US2018/037687 WO2018232202A1 (en) 2017-06-15 2018-06-15 Tetrahydropyridopyrazine modulators of gpr6
EP18818829.6A EP3638673B9 (en) 2017-06-15 2018-06-15 Tetrahydropyridopyrazine modulators of gpr6

Publications (1)

Publication Number Publication Date
HRP20241231T1 true HRP20241231T1 (hr) 2024-12-20

Family

ID=64656005

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241231TT HRP20241231T1 (hr) 2017-06-15 2018-06-15 Tetrahidropiridopirazin modulatori gpr6

Country Status (25)

Country Link
US (1) US10406157B2 (https=)
EP (1) EP3638673B9 (https=)
JP (2) JP7460369B2 (https=)
KR (1) KR102802861B1 (https=)
CN (1) CN110730781B (https=)
AU (1) AU2018285677B2 (https=)
CA (1) CA3067032A1 (https=)
CO (1) CO2019015086A2 (https=)
DK (1) DK3638673T3 (https=)
ES (1) ES2988680T3 (https=)
FI (1) FI3638673T3 (https=)
HR (1) HRP20241231T1 (https=)
HU (1) HUE068346T2 (https=)
IL (1) IL271332B2 (https=)
JO (1) JOP20180057A1 (https=)
LT (1) LT3638673T (https=)
MX (1) MX2019014940A (https=)
PH (1) PH12019502792A1 (https=)
PL (1) PL3638673T3 (https=)
PT (1) PT3638673T (https=)
RS (1) RS66018B1 (https=)
SG (1) SG11201912149WA (https=)
SI (1) SI3638673T1 (https=)
TW (1) TWI775874B (https=)
WO (1) WO2018232202A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067262A1 (zh) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 并环化合物、包含其的药物组合物及其用途和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Gpr6のピリドピラジンモジュレーター
KR20160122215A (ko) * 2014-02-14 2016-10-21 다케다 야쿠힌 고교 가부시키가이샤 Gpr6의 피라진 조절제

Also Published As

Publication number Publication date
EP3638673A4 (en) 2021-03-24
PT3638673T (pt) 2024-10-07
IL271332A (en) 2020-01-30
RS66018B1 (sr) 2024-11-29
EP3638673A1 (en) 2020-04-22
MX2019014940A (es) 2020-02-19
JOP20180057A1 (ar) 2019-01-30
KR102802861B1 (ko) 2025-04-30
JP2022188199A (ja) 2022-12-20
FI3638673T3 (fi) 2024-09-13
LT3638673T (lt) 2024-09-10
HUE068346T2 (hu) 2024-12-28
CA3067032A1 (en) 2018-12-20
KR20200014796A (ko) 2020-02-11
IL271332B (en) 2022-10-01
ES2988680T3 (es) 2024-11-21
US20180360831A1 (en) 2018-12-20
SI3638673T1 (sl) 2025-01-31
TWI775874B (zh) 2022-09-01
WO2018232202A1 (en) 2018-12-20
AU2018285677A1 (en) 2019-12-19
BR112019026430A2 (pt) 2020-07-14
EP3638673B9 (en) 2024-11-20
EP3638673B1 (en) 2024-07-17
CO2019015086A2 (es) 2020-04-13
AU2018285677B2 (en) 2022-07-14
TW201906844A (zh) 2019-02-16
JP7497400B2 (ja) 2024-06-10
SG11201912149WA (en) 2020-01-30
JP7460369B2 (ja) 2024-04-02
NZ759708A (en) 2024-04-26
JP2020523287A (ja) 2020-08-06
CN110730781B (zh) 2023-05-05
PL3638673T3 (pl) 2024-11-18
IL271332B2 (en) 2023-02-01
RU2019144408A (ru) 2021-07-15
US10406157B2 (en) 2019-09-10
CN110730781A (zh) 2020-01-24
DK3638673T3 (da) 2024-09-16
PH12019502792A1 (en) 2020-09-14
RU2019144408A3 (https=) 2021-09-07

Similar Documents

Publication Publication Date Title
RU2239429C2 (ru) Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
ES2279864T3 (es) Potenciacion de los efectos terapeuticos de los acidos grasos poliinsaturados.
JP2013505282A5 (https=)
Moore Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety
JP2015516395A5 (https=)
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
WO2009133141A3 (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
JP2009525985A5 (https=)
JP2009541237A (ja) 様々な型の痛みを予防、軽減及び/又は治療する医薬を製造するための、置換2−アミノテトラリンの使用
AR109300A2 (es) Formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
NZ592673A (en) Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
ZA200006817B (en) Combination therapy for treatment of Bipolar Disorders.
MA33553B1 (fr) Procede pour traiter un patient a risque de developper un ulcere associe aux ains
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
KR20010109275A (ko) 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
CN104955483A (zh) 用低剂量药剂治疗抑郁症和其它疾病
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
CN105407879A (zh) 与帕金森病治疗相关的副作用的治疗
Khan Off spells and dyskinesias: pharmacologic management of motor complications
HRP20241231T1 (hr) Tetrahidropiridopirazin modulatori gpr6
JP2007509146A5 (https=)
EP2321265A4 (en) INOSIT- AND TREHALOSEDERIVATES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES CONTAINING THEM
JP2012505830A5 (https=)
BR0308305A (pt) Fórmulas dosadas de liberação controlada
KR20220015407A (ko) 통증 치료를 위한 디아제팜 및 디클로페낙의 조합 투여